1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Metabolic Solutions Development Company, LLC - Product Pipeline Review - 2014

Metabolic Solutions Development Company, LLC - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Metabolic Solutions Development Company, LLC - Product Pipeline Review - 2014’, provides an overview of the Metabolic Solutions Development Company, LLC’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Metabolic Solutions Development Company, LLC’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Metabolic Solutions Development Company, LLC including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Metabolic Solutions Development Company, LLC’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Metabolic Solutions Development Company, LLC’s pipeline products

Reasons to buy

- Evaluate Metabolic Solutions Development Company, LLC’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Metabolic Solutions Development Company, LLC in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Metabolic Solutions Development Company, LLC’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Metabolic Solutions Development Company, LLC and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Metabolic Solutions Development Company, LLC
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Metabolic Solutions Development Company, LLC and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Metabolic Solutions Development Company, LLC - Product Pipeline Review - 2014
Table of Contents

Metabolic Solutions Development Company, LLC Snapshot 4
Metabolic Solutions Development Company, LLC Overview 4
Key Information 4
Key Facts 4
Metabolic Solutions Development Company, LLC - Research and Development Overview 5
Key Therapeutic Areas 5
Metabolic Solutions Development Company, LLC - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Metabolic Solutions Development Company, LLC - Pipeline Products Glance 9
Metabolic Solutions Development Company, LLC - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Metabolic Solutions Development Company, LLC - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
Metabolic Solutions Development Company, LLC - Drug Profiles 12
MSDC-0160 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
MSDC-0602 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Small Molecules for Type-2 Diabetes 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Metabolic Solutions Development Company, LLC - Pipeline Analysis 16
Metabolic Solutions Development Company, LLC - Pipeline Products by Route of Administration 16
Metabolic Solutions Development Company, LLC - Pipeline Products by Molecule Type 17
Metabolic Solutions Development Company, LLC - Recent Pipeline Updates 18
Metabolic Solutions Development Company, LLC - Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 23
Disclaimer 23

List of Tables

Metabolic Solutions Development Company, LLC, Key Information 4
Metabolic Solutions Development Company, LLC, Key Facts 4
Metabolic Solutions Development Company, LLC - Pipeline by Indication, 2014 6
Metabolic Solutions Development Company, LLC - Pipeline by Stage of Development, 2014 7
Metabolic Solutions Development Company, LLC - Monotherapy Products in Pipeline, 2014 8
Metabolic Solutions Development Company, LLC - Phase II, 2014 9
Metabolic Solutions Development Company, LLC - Preclinical, 2014 10
Metabolic Solutions Development Company, LLC - Discovery, 2014 11
Metabolic Solutions Development Company, LLC - Pipeline by Route of Administration, 2014 16
Metabolic Solutions Development Company, LLC - Pipeline by Molecule Type, 2014 17
Metabolic Solutions Development Company, LLC - Recent Pipeline Updates, 2014 18

List of Figures

Metabolic Solutions Development Company, LLC - Pipeline by Top 10 Indication, 2014 6
Metabolic Solutions Development Company, LLC - Pipeline by Stage of Development, 2014 7
Metabolic Solutions Development Company, LLC - Monotherapy Products in Pipeline, 2014 8
Metabolic Solutions Development Company, LLC - Pipeline by Top 10 Route of Administration, 2014 16
Metabolic Solutions Development Company, LLC - Pipeline by Top 10 Molecule Type, 2014 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.